IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q3 2024
Institutional positions in IO Biotech, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- 0 vs. Q2 2024
- Shares held
- 23.6M
- −2.59M (−9.9%) vs. Q2 2024
- Total value
- $24.8M
- −$5.87M (−19.1%) vs. Q2 2024
- New holders
- 5
- 3 more added
- Sold out
- 5
- 2 more reduced
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 6,173,439 | $6.48M | 0.54% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 3,640,015 | $3.82M | 0.73% | 00.0% | Unchanged |
| Novo Holdings A/S | 3,354,449 | $3.52M | 0.17% | −1,075,000−24.3% | Reduced |
| PFM Health Sciences, LP | 2,341,107 | $2.46M | 0.14% | 00.0% | Unchanged |
| Morgan Stanley | 2,202,085 | $2.31M | 0.00% | +229,742+11.6% | Added |
| Marshall Wace, LLP | 2,105,262 | $2.21M | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,651,515 | $1.73M | 0.00% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $907.4K | 0.54% | 00.0% | Unchanged |
| Logos Global Management LP | 493,827 | $518.5K | 0.06% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 199,623 | $209.6K | 0.00% | +75,000+60.2% | Added |
| Soleus Capital Management, L.P. | 192,670 | $202.3K | 0.02% | 00.0% | Unchanged |
| UBS Group AG | 107,906 | $113.3K | 0.00% | +104,626+3,189.8% | Added |
| Renaissance Technologies LLC | 97,000 | $101.8K | 0.00% | −83,800−46.3% | Reduced |
| Acadian Asset Management LLC | 60,650 | $63.0K | 0.00% | +60,650 | New |
| Marex Group plc | 45,000 | $47.3K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 33,307 | $35.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 30,000 | $31.5K | 0.00% | +30,000 | New |
| HRT Financial LP | 26,646 | $27.0K | 0.00% | +26,646 | New |
| Virtu Financial LLC | 17,954 | $19.0K | 0.00% | +17,954 | New |
| Advisor Group Holdings, Inc. | 230 | $242 | 0.00% | +230 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −1,545,000−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −314,600−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −86,894−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −26,555−100.0% | Sold out |
| Redwood Wealth Management Group, LLC | 0 | $0 | 0.00% | −4,166−100.0% | Sold out |